 - To identify a molecular profile, based on measurements of Estrogen Receptor ER, Epidermal Growth Factor Receptor EGFR, and a Human Epithelial Growth Factor Receptor-2HER2, and protein expression profiles in patients with treatment-naïve, operable breast cancer that is responsive to erlotinib hydrochloride. 